HER2 targeting by antibodies inhibited growth in association with persistent ROS generation, glutathione (GSH) depletion, reduction in NRF2 levels, and inhibition of NRF2 function in ovarian cancer cell lines. This evidence concerns the gene ERBB2 and ovarian carcinoma.